Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.

The New England journal of medicine - 31 Oct 2024

Turner Nicholas C, Im Seock-Ah, Saura Cristina, Juric Dejan, Loibl Sibylle, Kalinsky Kevin, Schmid Peter, Loi Sherene, Sunpaweravong Patrapim, Musolino Antonino, Li Huiping, Zhang Qingyuan, Nowecki Zbigniew, Leung Roland, Thanopoulou Eirini, Shankar Noopur, Lei Guiyuan, Stout Thomas J, Hutchinson Katherine E, Schutzman Jennifer L, Song Chunyan, Jhaveri Komal L

Abstract excerpt

BACKGROUND: Inavolisib is a highly potent and selective inhibitor of the alpha isoform of the p110 catalytic subunit of the phosphatidylinositol 3-kinase complex (encoded by PIK3CA) that also promotes the degradation of mutated p110α. Inavolisib plus palbociclib-fulvestrant has shown synergistic activity in preclinical models and promising antitumor activity in early-phase trials. METHODS: In a phase 3,...

Topics

Join the communities discussing this publication.

Breast Neoplasms, Male
Class I Phosphatidylinositol 3-Kinases
Double-Blind Method
Imidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Phosphoinositide-3 Kinase Inhibitors

Progression-Free Survival

Source

Identifiers

PMID: 39476340
DOI: 10.1056/NEJMoa2404625

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer.PMID 39476340Read ↗

Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer.Semantic proximity Read ↗

Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

Inavolisib: a second-generation PI3Kα inhibitor in HR+/HER2-negative breast cancer.Semantic proximity Read ↗

US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Semantic proximity Read ↗

Inavolisib for HR-Positive, HER2-Negative Advanced Breast Cancer: Clinical Trials and Patient Access Implication.Semantic proximity Read ↗

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read ↗

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models.Semantic proximity Read ↗

Safety analyses of the INAVO120 randomised phase III trial of inavolisib or placebo with palbociclib-fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative, endocrine-resistant advanced breast cancer.Semantic proximity Read ↗

Efficacy of PI3K inhibitors in advanced breast cancer.Semantic proximity Read ↗

Alpelisib to treat breast cancer.Semantic proximity Read ↗

Economic Evaluation of Inavolisib Combined With Palbociclib-Fulvestrant for PIK3CA-Mutated, HR+/HER2- Advanced Breast Cancer in USA.Semantic proximity Read ↗

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.